Pharmacological effects of methylone and MDMA in humans

Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we aimed to evaluate the acute pharmacological effects of methylone and its abuse potential in humans when compared with that of MDMA following oral administration under controlled conditions. Seventeen participants of both sexes (14 males, 3 females) with a previous history of psychostimulant use completed a randomized, double-blind, placebo-controlled, crossover clinical trial. Participants received a single oral dose of 200 mg of methylone, 100 mg of MDMA, and a placebo. The variables included physiological effects (blood pressure, heart rate, oral temperature, pupil diameter), subjective effects using visual analog scales (VAS), the short form of the Addiction Research Center Inventory (ARCI), the Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire (VESSPA-SSE), and the Sensitivity to Drug Reinforcement Questionnaire (SDRQ), and psychomotor performance (Maddox wing, psychomotor vigilance task). We observed that methylone could significantly increase blood pressure and heart rate and induce pleasurable effects, such as stimulation, euphoria, wellbeing, enhanced empathy, and altered perception. Methylone exhibited an effect profile similar to MDMA, with a faster overall onset and earlier disappearance of subjective effects. These results suggest that abuse potential of methylone is comparable to that of MDMA in humans. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05488171; Identifier: NCT05488171.

[1]  C. Pittenger,et al.  Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity , 2023, Frontiers in Psychiatry.

[2]  M. Huestis,et al.  Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans , 2022, International journal of molecular sciences.

[3]  H. Gréen,et al.  Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis , 2022, Basic & clinical pharmacology & toxicology.

[4]  M. Farré,et al.  Abuse Potential of Cathinones in Humans: A Systematic Review , 2022, Journal of clinical medicine.

[5]  M. Barratt,et al.  Wastewater analysis for psychoactive substances at music festivals across New South Wales, Australia in 2019–2020 , 2021, Clinical toxicology.

[6]  R. de la Torre,et al.  A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure , 2021, Biology.

[7]  Jennifer M. Mitchell,et al.  MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study , 2021, Nature Medicine.

[8]  K. Rice,et al.  Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects , 2021, The Journal of Pharmacology and Experimental Therapeutics.

[9]  M. Liechti,et al.  Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies , 2021, Journal of psychopharmacology.

[10]  Julie B. Wang,et al.  MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study , 2020, Scientific Reports.

[11]  Julie B. Wang,et al.  RETRACTED ARTICLE: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials , 2020, Psychopharmacology.

[12]  S. Borgwardt,et al.  Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects , 2019, Neuropsychopharmacology.

[13]  M. Liechti,et al.  Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems , 2019, Journal of psychopharmacology.

[14]  R. Giorgetti,et al.  Nails Analysis for Drugs Used in the Context of Chemsex: A Pilot Study. , 2019, Journal of analytical toxicology.

[15]  J. Reifman,et al.  PC-PVT 2.0: An updated platform for psychomotor vigilance task testing, analysis, prediction, and visualization , 2018, Journal of Neuroscience Methods.

[16]  J. Ramaekers,et al.  Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine , 2018, Psychopharmacology.

[17]  T. Dickerson,et al.  Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats , 2017, Neuropharmacology.

[18]  M. Balíková,et al.  Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats , 2017, Front. Psychiatry.

[19]  J. Palamar,et al.  Hair testing to assess both known and unknown use of drugs amongst ecstasy users in the electronic dance music scene. , 2017, The International journal on drug policy.

[20]  M. Taffe,et al.  Escalation of intravenous self‐administration of methylone and mephedrone under extended access conditions , 2017, Addiction biology.

[21]  J. Palamar,et al.  Hair Testing for Drugs of Abuse and New Psychoactive Substances in a High-Risk Population. , 2017, Journal of analytical toxicology.

[22]  S. Deroux,et al.  “Bath Salts” the New York City Medical Examiner Experience: A 3‐Year Retrospective Review , 2017, Journal of forensic sciences.

[23]  M. Liechti,et al.  Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies , 2017, Journal of psychopharmacology.

[24]  M. Liechti,et al.  Presentations to an urban emergency department in Bern, Switzerland associated with acute recreational drug toxicity , 2017, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[25]  Jason M. White,et al.  National Wastewater Drug Monitoring Program - Report 1 , 2017 .

[26]  Kayla N. Ellefsen,et al.  Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats , 2017, Neuropsychopharmacology.

[27]  R. de la Torre,et al.  Neurocognitive performance following acute mephedrone administration, with and without alcohol , 2016, Journal of psychopharmacology.

[28]  M. Farré,et al.  Human Pharmacology of Mephedrone in Comparison with MDMA , 2016, Neuropsychopharmacology.

[29]  C. Lançon,et al.  The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences , 2016, Brain Research Bulletin.

[30]  E. Shimomura,et al.  Case Report of Methylone, Oxymorphone and Ethanol in a Fatality Case with Tissue Distribution. , 2016, Journal of analytical toxicology.

[31]  M. Barratt,et al.  Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. , 2016, The American journal on addictions.

[32]  Kurt R. Lehner,et al.  Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats , 2016, Psychopharmacology.

[33]  D. Boels,et al.  Death following ingestion of methylone , 2016, International Journal of Legal Medicine.

[34]  M. Taffe,et al.  Intravenous self-administration of entactogen-class stimulants in male rats , 2015, Neuropharmacology.

[35]  M. Taffe,et al.  Intravenous self-administration of mephedrone, methylone and MDMA in female rats , 2015, Neuropharmacology.

[36]  M. Liechti,et al.  MDMA effects consistent across laboratories , 2014, Psychopharmacology.

[37]  M. Liechti,et al.  Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. , 2014, The international journal of neuropsychopharmacology.

[38]  Iain M McIntyre,et al.  Acute methylone intoxication in an accidental drowning--a case report. , 2013, Forensic science international.

[39]  Jorge Camarasa,et al.  An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts” , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  A. Janowsky,et al.  Substituted methcathinones differ in transporter and receptor interactions. , 2013, Biochemical pharmacology.

[41]  Nathalie A. Desrosiers,et al.  Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration , 2013, Analytical and Bioanalytical Chemistry.

[42]  M. Liechti,et al.  Pharmacological characterization of designer cathinones in vitro , 2013, British journal of pharmacology.

[43]  Scott A Luzi,et al.  Sudden Cardiac Death Associated With Methylone Use , 2012, The American journal of forensic medicine and pathology.

[44]  D. Fowler,et al.  Distribution of methylone in four postmortem cases. , 2012, Journal of analytical toxicology.

[45]  U. Garg,et al.  Three fatal intoxications due to methylone. , 2012, Journal of analytical toxicology.

[46]  R. Rothman,et al.  The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue , 2012, Neuropsychopharmacology.

[47]  B. Blough,et al.  The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts" , 2012, Journal of addiction research & therapy.

[48]  M. St-Onge,et al.  Seizures and Hyponatremia Related to Ethcathinone and Methylone Poisoning , 2012, Journal of Medical Toxicology.

[49]  C. Aaron,et al.  Lethal Serotonin Syndrome After Methylone and Butylone Ingestion , 2012, Journal of Medical Toxicology.

[50]  M. Liechti,et al.  Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. , 2011, The Journal of clinical endocrinology and metabolism.

[51]  I. Sora,et al.  Methylone and Monoamine Transporters: Correlation with Toxicity , 2011, Current neuropharmacology.

[52]  U. McCann,et al.  Further Studies on the Role of Metabolites in (±)-3,4-Methylenedioxymethamphetamine-Induced Serotonergic Neurotoxicity , 2009, Drug Metabolism and Disposition.

[53]  J. Ramaekers,et al.  Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night , 2007, Psychopharmacology.

[54]  R. Croft,et al.  The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance , 2006, Psychopharmacology.

[55]  J. Ramaekers,et al.  Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol , 2006, Neuropsychopharmacology.

[56]  M. Bossong,et al.  Methylone and mCPP, two new drugs of abuse? , 2005, Addiction biology.

[57]  M. Farré,et al.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics , 2004, Psychopharmacology.

[58]  M. F. Albaladejo,et al.  Construcción de un cuestionario para la Valoración de los Efectos Subjetivos de Sustancias con Potencial de Abuso (VESSPA): Evaluación del éxtasis , 2003 .

[59]  R. de la Torre,et al.  Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. , 2000, Journal of clinical psychopharmacology.

[60]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[61]  M. Farré,et al.  Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). , 1994, Drug and alcohol dependence.

[62]  Peter Widler,et al.  Pharmacodynamics and pharmacokinetics of khat: A controlled study , 1994, Clinical pharmacology and therapeutics.

[63]  P. Kalix,et al.  Amphetamine-like effects in humans of the khat alkaloid cathinone. , 1990, British journal of clinical pharmacology.

[64]  H. S. Davis,et al.  A Controlled Study , 1966 .